Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Healthcare Collaboration and Partnerships


Excellence in Healthcare Collaboration and Partnerships

Health providers such as the NHS and the pharmaceutical industry share a common agenda to improve patient care outcomes through high quality, cost effective treatment and management. 


The common agenda is to improve patient outcomes through joint working to ensure that patients get optimal care, with support to help them maximise the benefits of treatment. 


Eligible work will demonstrate joint development and implementation of patient-centred projects together with shared commitment to successful delivery. These may have operated at a local or national level.


This category relates to work carried out between July 2011 and December 2012.


Potential entrants might include:


  • Pharmaceutical company brand teams
  • Pharmaceutical company communications teams
  • Healthcare agencies and consultancies. 


Judging criteria:


  • Clear understanding of customer needs and objectives
  • Demonstration of partnership between (two or more) players:
  • shared objectives
  • pooled skills, experience and/or resources 
  • Evidence of sustained relationships and mutual benefit
  • Evidence of changed behaviours and enhanced health outcomes 
  • Customer feedback

Sponsors

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences. We help our...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics